Facebook Twitter LinkedIn Instagram Email Printer Google Plus


As the Biden administration leans into the Cancer Moonshot 2.0, the life sciences industry has the opportunity to launch a new era of precision oncology. How can we accelerate progress toward truly personalized medicine and revolutionize cancer care?

Chief Strategy Officer, COTA, Inc.

Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.

Global Head, Health Services, Oliver Wyman
Professor of Surgery and Health Policy, Johns Hopkins Medicine
Principal, Health and Life Sciences, Oliver Wyman

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

The election results sent biopharma stock soaring. Breaking down what’s really on tap for biopharma over the next four years.

Partner, Health & Life Sciences, Oliver Wyman
Engagement Manager, Health & Life Sciences Practice, Oliver Wyman

Through this series of infographics, learn how payers, providers, and life sciences companies will be impacted by our 45th president.

Global Leader, Health and Life Sciences, Oliver Wyman

Insights in your inbox